Stage III Pancreatic Cancer Clinical Trial
Official title:
A Phase II Study of Bevacizumab With Concurrent Capecitabine and Radiation Followed by Maintenance Gemcitabine and Bevacizumab For Locally Advanced Pancreatic Cancer
Verified date | October 2020 |
Source | National Cancer Institute (NCI) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Drugs used in chemotherapy, such as capecitabine and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of pancreatic cancer by blocking blood flow to the tumor. Radiation therapy uses high-energy x-rays to kill tumor cells. Capecitabine may make tumor cells more sensitive to radiation therapy. Bevacizumab may make tumor cells more sensitive to both chemotherapy and radiation therapy. Giving chemotherapy and bevacizumab before and after radiation therapy may kill more tumor cells. This phase II trial is studying how well giving capecitabine and bevacizumab together with radiation therapy followed by gemcitabine and bevacizumab works in treating patients with locally advanced pancreatic cancer that cannot be removed by surgery.
Status | Completed |
Enrollment | 82 |
Est. completion date | May 2007 |
Est. primary completion date | May 2007 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Histologically confirmed adenocarcinoma of the pancreas - Locally advanced disease - Unresectable disease - All malignant disease must be encompassable within a single irradiation field - Radiographically assessable disease - Patients with biliary or gastroduodenal obstruction are eligible provided drainage or surgical bypass was performed prior to initiation of study treatment - No evidence of gastric outlet obstruction - No evidence of duodenal invasion on CT scan - No evidence of metastatic disease in the major viscera - No peritoneal seeding or ascites - Performance status - Zubrod 0-1 - Granulocyte count = 1,500/mm^3 - Platelet count = 100,000/mm^3 - No evidence of bleeding diathesis - ALT < 3 times upper limit of normal - Bilirubin < 2.0 mg/dL - INR = 1.5 - No evidence of coagulopathy - Creatinine clearance > 50 mL/min - Urine protein < 1,000 mg by 24-hour urine collection (for patients with proteinuria = 1+ by dipstick or urinalysis OR urine protein:creatinine ratio = 1.0) - No myocardial infarction within the past 6 months - No unstable angina within the past 6 months - No arterial thromboembolic events within the past 6 months, including any of the following: - Transient ischemic attack - Cerebrovascular accident - Clinically significant peripheral artery disease - No unstable symptomatic arrhythmia requiring medication (e.g., chronic atrial arrhythmia [i.e., atrial fibrillation or paroxysmal supraventricular tachycardia]) - Patients with an atrial arrhythmia are eligible provided the condition is well controlled on stable medication - No New York Heart Association class II-IV congestive heart failure - No history of arteriovenous malformation - No history of aneurysm - No uncontrolled hypertension (i.e., blood pressure > 160/90 mm Hg with medication) - No other clinically significant cardiac disease - No AIDS - No significant infection - No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies - Not pregnant - No nursing during and for = 3-4 months after completion of study treatment - Negative pregnancy test - Fertile patients must use effective contraception during and for = 3-4 months after completion of study treatment - No history of gastrointestinal fistula or perforation - No other malignancy within the past two years except nonmelanoma skin cancer or carcinoma in situ of the cervix, uterus, or bladder - No significant traumatic injury within the past 4 weeks - No serious nonhealing wound or ulcer - No current healing fracture - No known or suspected dihydropyrimidine dehydrogenase deficiency - No other medical condition that would preclude study participation - No concurrent interleukin-11 - No prior chemotherapy for pancreatic cancer - More than 2 years since prior chemotherapy for another malignancy - No prior radiotherapy to the planned irradiation field - No concurrent intensity modulated radiotherapy - No other concurrent radiotherapy - See Disease Characteristics - More than 4 weeks since prior major surgical procedure or open biopsy - More than 1 week since prior fine needle aspiration or core biopsy - No prior organ transplantation - No concurrent major surgical procedure - More than 30 days since prior and no concurrent cimetidine - Concurrent ranitidine or a drug from another anti-ulcer class allowed - More than 4 weeks since prior and no concurrent sorivudine or brivudine - No concurrent warfarin during chemoradiotherapy - Concurrent warfarin allowed beginning 2 weeks after completion of chemoradiotherapy - Concurrent low molecular weight heparin allowed (at any time during study participation) - No other concurrent investigational agents - No other concurrent cytotoxic agents |
Country | Name | City | State |
---|---|---|---|
United States | Radiation Therapy Oncology Group | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) | NRG Oncology |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall survival rate | Will be estimated using the Kaplan-Meier method. | 1 year | |
Secondary | Frequency of patients developing grade 3 or greater adverse events as defined per CTCAE version 3.0 | Up to 1 year | ||
Secondary | Progression-free survival | Will be estimated using the Kaplan-Meier method. | Up to 1 year | |
Secondary | Response rate | Up to 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01959672 -
Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer
|
Phase 2 | |
Terminated |
NCT02495896 -
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Terminated |
NCT02345460 -
Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study
|
Phase 2 | |
Completed |
NCT00095966 -
Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
|
Phase 2 | |
Completed |
NCT00020345 -
Combination Chemotherapy and Radiation Therapy Plus Surgery in Treating Patients With Advanced Cancer of the Pancreas
|
Phase 2 | |
Completed |
NCT02897375 -
Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT01846520 -
Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers
|
N/A | |
Completed |
NCT01191684 -
Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT02896907 -
Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery
|
Early Phase 1 | |
Completed |
NCT01068327 -
Stereotactic Radiation, Nelfinavir Mesylate & Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT02307539 -
Palliative Care in Improving Quality of Life in Patients With Newly Diagnosed Pancreatic Cancer
|
N/A | |
Completed |
NCT01222689 -
Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
|
Phase 2 | |
Completed |
NCT00026104 -
Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer
|
Phase 2 | |
Completed |
NCT00028496 -
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03899649 -
A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer
|
||
Completed |
NCT01821612 -
Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients With Pancreatic Cancer
|
Early Phase 1 | |
Terminated |
NCT01739439 -
Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery
|
Phase 1 | |
Completed |
NCT01131234 -
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT00323583 -
Weekly Dosing of an Integrative Chemotherapy Combination to Treat Advanced Pancreatic Cancer
|
Phase 2 | |
Terminated |
NCT00087191 -
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
|
N/A |